A Safety, Tolerability, and Pharmacokinetic Study of Injections of LY3074828 Solution Using Investigational 1-mL Pre-filled Syringes and Investigational 1-mL Autoinjector in Healthy Subjects
Latest Information Update: 22 Feb 2024
At a glance
- Drugs Mirikizumab (Primary)
- Indications Crohn's disease; Plaque psoriasis; Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
Most Recent Events
- 07 Nov 2019 Status changed from active, no longer recruiting to completed.
- 19 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Jul 2019 Planned End Date changed from 3 Sep 2019 to 4 Oct 2019.